Press Release Jul 18 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
This antifungal treatment is intended for the topical management of toenail infections caused by specific fungi. The drug will be produced at the company's manufacturing facility in Ahmedabad, India. The press release highlights that the approved product had significant annual sales in the United States.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jul 11 2022
- Press Release Jul 08 2022
- Press Release Jun 30 2022
- Press Release Jun 07 2022
- Press Release Jun 06 2022
Later from Zydus Lifesciences
- Press Release Jul 21 2022
- Press Release Jul 26 2022
- Press Release Aug 04 2022
- Press Release Aug 05 2022
- Press Release Aug 11 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences